Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when the Joint Committee on Vaccination and Immunisation last reviewed the cost-effectiveness model for providing the Meningitis B vaccine to teenagers; and whether his Department plans to commission an updated model.

In 2013, the Joint Committee on Vaccination and Immunisation (JCVI) advised that the cost-effectiveness of an adolescent Meningitis B (MenB) vaccination programme would be dependent on the impact of the vaccine on protection against meningococcal carriage, which was uncertain at the time. Since this advice was published, the JCVI has continued to review the MenB vaccination programme. Recent evidence, discussed by the JCVI meningococcal sub-committee in March 2025, indicated that MenB vaccination in adolescents has little to no effect on meningococcal carriage.

The sub-committee noted that when available, they would like to review a model evaluating the impact of MenB vaccine when given in a teenage programme in a two-dose schedule, including impact on meningococcal disease and gonorrhoea.